In this article we will check out the progression of hedge fund sentiment towards Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) and determine whether it is a good investment right now.
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming).
Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good.
Tetraphase Pharmaceuticals Inc's Ignite3 trial evaluating the company's lead drug candidate eravacycline for treating complicated urinary tract infections, or cUTIs, failed to ace a late-stage trial.
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing ...
As the main indices are heading towards ending today's session in the green territory, let's take a look at five stocks that are registering significant gains today.